The burden of hyperkalemia in patients with cardiovascular and renal disease

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Hyperkalemia (high potassium) is a serious condition linked to life-threatening cardiac arrhythmias and increased mortality.
• Patients over 65 with advanced chronic kidney disease (CKD stage 3+), diabetes, or chronic heart failure are at elevated risk.
• Renin-angiotensin-aldosterone system (RAAS) inhibitors are recommended for these patients but can increase hyperkalemia risk.

Purpose of the Study:

• To highlight the unmet need for effective chronic hyperkalemia management strategies.
• To discuss the limitations of current hyperkalemia treatments, particularly in patients requiring RAAS inhibitors.
• To emphasize the potential impact of novel therapies on patient outcomes and healthcare costs.

Main Methods:

• This is a review and discussion of the current literature and clinical challenges in hyperkalemia management.
• Analysis of the risks and benefits associated with RAAS inhibitors in high-risk patient populations.
• Identification of the limitations of existing acute and chronic hyperkalemia treatment options.

Main Results:

• Current chronic hyperkalemia management often necessitates reducing or discontinuing beneficial RAAS inhibitors or imposing strict dietary restrictions.
• Withholding RAAS inhibitors can lead to poorer cardiovascular and renal outcomes, including end-stage renal disease and increased mortality.
• Existing short-term treatments for acute hyperkalemia are effective but lack long-term control capabilities.

Conclusions:

• There is a significant unmet need for novel therapeutic options for the chronic management of hyperkalemia.
• Effective long-term hyperkalemia control is crucial to allow continued use of RAAS inhibitors, thereby improving cardiovascular and renal outcomes.
• Emerging therapies in development hold promise for transforming the treatment landscape for at-risk patients.